DANBURY, Conn.--(BUSINESS WIRE)--IMS Health (NYSE:IMS) today announced a multi-year agreement with Valeant Canada, a business unit of Valeant Pharmaceuticals, to deploy IMS Health’s next-generation Orchestrated Customer Engagement (OCE) solution for advancing commercial effectiveness. The OCE solution for Valeant Canada integrates Nexxus™ Mobile Intelligence CRM, Nexxus Marketing, cloud-based data warehousing and business intelligence analytics—leveraging IMS Heath’s industry-leading information and technology services to deliver intelligence and enhanced sales and marketing performance for improved customer interactions.
IMS Health’s solution uniquely aligns mission-critical healthcare information and innovative SaaS applications for sales, marketing and market access—empowering life sciences organizations to better coordinate customer engagement and achieve their commercial goals.
Tightly synchronized with the IMS One™ cloud platform, OCE connects and streamlines complex processes in commercial management, from multi-channel marketing and social media monitoring to analytics for performance management. This end-to-end approach addresses the challenge of strengthening the relationship between life sciences companies and their customers, while increasing efficiency across all communication channels and boosting marketing ROI.
“We selected IMS Health’s integrated CRM, multi-channel marketing and data solutions to leverage our sales team’s strengths, while increasing our investment in tools that coordinate all channels of communication,” said Jacques Dessureault, president and general manager of Valeant Canada. “Valeant Canada is built on a history of continuous innovation, and the speed and flexibility of IMS Health’s capabilities will make our interactions with customers even more efficient and productive.”
Valeant Canada is focused on empowering its commercial teams with relevant insights and a 360-degree view of their customers for excellence in sales execution. The company wanted to quickly implement a scalable solution that makes information and analytics easily accessible to its sales, marketing and technology teams, whenever and wherever they choose. With OCE, Valeant Canada can link more extensive and granular data with agile cloud-based applications, enabling a fully coordinated approach to the increasingly complex multi-channel and multi-stakeholder market environment.
“We’re excited to collaborate with Valeant Canada to help them uncover valuable insights and drive faster, more effective decisions,” said Michael Brogan, president of IMS Health Canada. “With our orchestrated customer engagement solution, Valeant can now optimize workflows across commercial functions and more closely align market engagement with its brand strategy.”
For more information about IMS Health solutions, visit www.imshealth.com.
About Valeant Pharmaceuticals
Valeant Pharmaceuticals is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorder, eye health, neurology and branded generics.
About IMS Health
IMS Health is a leading global information and technology services company providing clients in the healthcare industry with end-to-end solutions to measure and improve their performance. Our 7,500 services experts connect configurable SaaS applications to 10+ petabytes of complex healthcare data in the IMS One™ cloud platform, delivering unique insights into diseases, treatments, costs and outcomes. The company’s 15,000 employees blend global consistency and local market knowledge across 100 countries to help clients run their operations more efficiently. Customers include pharmaceutical, consumer health and medical device manufacturers and distributors, providers, payers, government agencies, policymakers, researchers and the financial community.
As a global leader in protecting individual patient privacy, IMS Health uses anonymous healthcare data to deliver critical, real-world disease and treatment insights. These insights help biotech and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders to identify unmet treatment needs and understand the effectiveness and value of pharmaceutical products in improving overall health outcomes. Additional information is available at www.imshealth.com.